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Objective: The aim of this study was to identify factors that influence treatment adjustments 
and adoption of a treat-to-target (T2T) strategy in patients with rheumatoid arthritis (RA) in 
European practices.
Methods: Cross-sectional data were drawn from the Adelphi 2014 RA Disease Specific Pro-
gramme. Treatment patterns and clinical characteristics were investigated in patients treated 
with biologic disease-modifying antirheumatic drugs (bDMARDs) vs non-bDMARDs. For the 
T2T analysis, patients were subdivided into two subsets (RA diagnosis ,2 or $2 years) and 
compared according to the approach used (no target = no T2T approach; pragmatic = target 
different from remission; and aspirational = target set as remission).
Results: Data from 2,536 patients were analyzed (mean age: 52.76 years and mean time since 
RA diagnosis: 6.05 years). Of the 1,438 patients eligible to receive bDMARDs, 55% did not 
receive them. Initiation of bDMARDs in a bDMARD-naïve patient was prompted by worsening 
of the disease. In the RA diagnosis ,2 years subset, a T2T approach was not adopted in 58% of 
the patients, whereas 8% and 34% adopted a pragmatic and aspirational approach, respectively. 
In the RA diagnosis $2 years subset, 45%, 19%, and 36% of the patients adopted a no target, 
pragmatic, and aspirational approach, respectively. Physician satisfaction with RA control was 
lower in the RA diagnosis ,2 years subset than in the RA diagnosis $2 years subset (65% vs 
77% satisfied, respectively; P,0.0001).
Conclusion: This analysis shows that the use of bDMARDs remains suboptimal and that a 
T2T strategy is not universally adopted.
Keywords: rheumatoid arthritis, treat-to-target, disease-modifying antirheumatic drugs
Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflam-
mation and deterioration of the joints. RA causes significant loss of functionality and 
increases morbidity and mortality.1
Treatment for RA involves early initiation of disease-modifying antirheumatic 
drugs (DMARDs).2,3 Current European League Against Rheumatism (EULAR) recom-
mendations support the use of conventional synthetic DMARDs (csDMARDs), such 
as methotrexate, as first-line therapy, combined with glucocorticoids for a limited 
time. Biologic DMARDs (bDMARDs) or targeted synthetic DMARDs (tsDMARDs) 
may be combined with a csDMARD if csDMARD therapy fails.3 The wide array of 
DMARDs available enables optimum disease management by allowing monotherapy 
or combination therapy, different dose titrations, and treatment switching. The rec-
ommendations suggest that treatment assessments should be made every 1–3 months 
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in patients with high-to-moderate disease activity and that 
therapy adjustments should be made every 3–6 months if the 
target has not been reached.2
EULAR recommendations state that the primary target 
for all patients with RA should be sustained remission or low 
disease activity (LDA), the latter for patients with long-standing 
or aggressive disease.3 In addition, the American College of 
Rheumatology (ACR) recommends an aggressive therapy 
approach in patients with early RA to achieve better outcomes 
and prevent damage progression.2 Indeed, early RA evaluation 
and treatment appear to be critical in optimizing the subsequent 
response.4,5 Better disease control can be achieved by adopting a 
treat-to-target (T2T) approach, which has been shown to be ben-
eficial in various illnesses.6–10 This strategy is based on setting 
therapeutic targets that are reached through frequent assessments 
and drug therapy adjustments in order to optimize treatment. 
The assessments require measurement of disease activity using 
validated metrics to enable informed treatment decisions. A T2T 
approach is widely accepted to improve outcomes in patients 
with RA,11–13 but has not been universally adopted.14
One of the aims of this study was to identify the factors 
influencing the introduction of bDMARD treatment in RA 
patients in a real-world setting, the choice of a specific 
bDMARD, and switching from one class of bDMARD to 
another. A further objective was to assess the adoption of a 
T2T strategy for the treatment of RA and physician satisfaction 
with different targets in the T2T management approach.
Methods
Study design
This was an analysis of cross-sectional data drawn from the 
Adelphi 2014 RA Disease Specific Programme (DSP), a 
point-in-time survey of rheumatologists and their patients with 
RA. The DSP aims to provide impartial observations of real-
world clinical practice from a physician and matched patient 
viewpoint without consideration of current guidelines, but 
with the intention of providing a view on contemporary RA 
management. The survey was conducted in France, Germany, 
Italy, Spain, and the UK from January to August 2014. 
Patients provided written informed consent for use of their 
anonymized and aggregated data for research and publication 
in scientific journals. For each patient meeting the eligibility 
criteria, the physicians filled out a patient record form (PRF), 
which included questions on demographics, symptoms, past 
and current treatments, compliance, and general patient 
management. Data were collected in such a way that patients 
and physicians could not be identified directly; all data were 
aggregated and de-identified before receipt. Data collection 
was undertaken in line with the European Pharmaceutical 
Marketing Research Association (EPhMRA) guidelines and 
as such it did not require ethics committee approval.15 The 
survey was performed in full accordance with relevant leg-
islation at the time of data collection, including the Health 
Insurance Portability and Accountability Act,16 a cornerstone 
of the EPhMRA guidelines relating to data privacy.
Local fieldwork teams identified and invited rheuma-
tologists to participate in the study upon fulfillment of the 
inclusion criteria listed subsequently. Compensation was set 
according to time spent on the study at fair market rates. Each 
rheumatologist recruited the first eight consecutive patients 
who consulted them and satisfied the inclusion criteria.
For the analysis of bDMARD use, the clinical and disease 
characteristics and satisfaction level of patients with moderate-
to-severe RA were compared among patients who received 
a bDMARD vs those who did not (non-bDMARD). For the 
assessment of adoption of a T2T approach/strategy, as this 
approach is particularly recommended during the early phase 
of the disease, the patients were subdivided into two subsets: 
RA diagnosis ,2 years and RA diagnosis $2 years. Physi-
cians indicated the T2T goal they adopted as either remission 
(defined as disease activity score in 28 joints [DAS28],2.6), 
LDA (DAS28 ,3.2), or other target. Patients were subse-
quently compared according to the T2T approach used: no 
target (patients treated without a T2T approach), pragmatic 
(T2T target set as LDA or something other than remission), 
or aspirational (T2T goal set as remission).
Physicians and patients
Only rheumatologists who qualified between 1975 and 2010 
and who were actively involved in RA management were 
included in the DSP. In addition, rheumatologists were 
required to manage more than eight patients with RA in a 
calendar month. Patients with RA were eligible for inclu-
sion if they were $18 years of age and were not involved 
in clinical trials for RA. In order to be considered eligible 
for bDMARD therapy, patients had to have received at 
least one csDMARD before their current treatment, have 
moderate-to-severe RA at the initiation of their current 
treatment (as reported by the physician), and remain on that 
current treatment for $6 months to determine effectiveness. 
In addition, these patients had to have consulted a physician 
who was authorized to initiate bDMARDs. Assessment of 
the severity of RA (mild, moderate, or severe) was based on 
the physician’s own perception of the disease status. For the 
assessment of the adoption of a T2T strategy, patients with 
an unknown time since RA diagnosis were excluded.
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Statistical analyses
Mean and standard deviation (SD) for numerical outcomes 
and frequency and percentage of patients within each 
response for nominal outcomes were reported. Statisti-
cal differences were assessed using Mann–Whitney U or 
Kruskal–Wallis test for numeric outcomes, and chi-squared 
or Fisher’s exact test for nominal outcomes.
Missing data were not imputed. Any patients with missing 
values for a particular variable were removed for all analyses 
where that variable was used, but remained eligible for inclu-
sion in other analyses.
Results
Overall, 307 rheumatologists provided data on a total of 2,536 
patients from across Europe (France: n=502; Germany: n=491; 
Italy: n=501; Spain: n=486; and UK: n=556). The mean (SD) 
age of the patients was 52.76 (14.32) years and the mean (SD) 
time since diagnosis of RA was 6.05 (6.81) years (Table 1). 
The majority (71%) of the patients were women, and 63% of 
the patients had never received bDMARDs. Of the 37% of 
patients (n=926) who had previously received a bDMARD, 
93% of these were currently receiving bDMARD therapy (the 
remaining 7% had discontinued bDMARD therapy) and 68% 
had received only one prior bDMARD therapy.
For the analysis of bDMARD use, 126 patients were 
excluded because it could not be determined whether these 
patients were receiving bDMARD or non-bDMARD treat-
ment at the time of the survey due to missing or contradictory 
information. Clinical characteristics of the remaining patients 
are shown in Table 2. The patients on bDMARD therapy had 
a significantly longer time since RA diagnosis compared with 
the patients who were not on a bDMARD (8.62 vs 6.69 years, 
respectively; P,0.0001). These patients also had a more 
severe condition at the initiation of their current treatment as 
perceived by rheumatologists (52% vs 27% with severe RA, 
respectively; P,0.0001) and were experiencing more pain at 
the initiation of their current treatment (mean levels of pain 
on a 1–10 scale were 7.13 vs 6.44, respectively; P,0.0001; 
Table 2). The two main reasons why rheumatologists chose 
to initiate bDMARD therapy in patients receiving bDMARDs 
were “strong overall efficacy” of bDMARD therapy (71%) 
and “convincing efficacy shown in clinical trials” (55%; 
Figure 1A). When switching between bDMARD therapies 
occurred, the principal reasons that prompted the patient’s 
most recent change in bDMARD treatment were “worsen-
ing of the condition” (46%) and “loss of response over 
time” (38%; Figure 1B). Second-line bDMARD therapies 
were chosen based on similar reasons as for the first-line 
bDMARDs, even when switching to a different class of 
bDMARD. The main reasons that would prompt initiation 
of a bDMARD in those patients who were still bDMARD-
naïve (as stated by the physician) were worsening of the 
disease (61%) and failure of non-bDMARD therapy (33%) as 
assessed by the physician (Figure 1C). In 7% of the patients, 
physicians stated that nothing would prompt bDMARD 
initiation (ie, bDMARDs were likely contraindicated).
Only patients for whom the time since RA diagnosis was 
known were included in the assessment of T2T strategy adop-
tion (n=2,381). The baseline characteristics of these patients 
are shown in Table 3. Twenty-four percent of the patients 
(n=579) had been diagnosed with RA for ,2 years and 76% 
(n=1,802) for $2 years. A T2T approach was not adopted 
(“no target”) in 1,144 patients (regardless of time since RA 
diagnosis), whereas physicians adopted a pragmatic approach 
in 395 patients and an aspirational approach in 842 patients. 
A higher proportion of patients in the RA diagnosis ,2 years 
subset had no target than those in the $2 years subset (58% vs 
45%, respectively; Table 3), and fewer had a pragmatic one 
(8% vs 19%, respectively; Table 3). The percentage of patients 
with an aspirational target was similar in both subsets (34% 
vs 36%, respectively; Table 3). In the ,2 years subset, 7–9% 
of the patients were currently receiving bDMARDs across all 
T2T subgroups, whereas in the $2 years subset, 38%, 42%, 
and 52% of the patients received bDMARDs in the no 
target, pragmatic, and aspirational subgroups, respectively.
Physician satisfaction with RA control was lower in 
the RA diagnosis ,2 years subset than in the RA diag-
nosis $2 years subset (65% [377/579] vs 77% [1,387/1,802] 
satisfied, respectively). In the RA diagnosis ,2 years subset, 
Table 1 Overall patient demographics
Characteristics Patients 
(N=2,536)
Age, years, mean (SD)a 52.76 (14.32)
Female, n (%) 1,808 (71)
BMI, kg/m2, mean (SD)b 25.22 (4.29)
Time since RA diagnosis, years, mean (SD)c 6.05 (6.81)
Disease severity at the initiation of current treatment, n (%)
Mild
Moderate
severe
345 (14)
1,417 (56)
774 (31)
Prior bDMARD therapy, n (%)
Yes
no
Currently still receiving bDMARD therapyd
926 (37)
1,610 (63)
859 (93)
Notes: aData missing from eleven patients. bData missing from two patients. cData 
missing from 155 patients. dData are a subset of the 926 patients in the ‘Yes’ category 
of this variable.
Abbreviations: bDMARD, biologic disease-modifying antirheumatic drug; BMI, 
body mass index; RA, rheumatoid arthritis.
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physician-reported satisfaction with RA control differed 
significantly across T2T subgroups and was highest in the 
“no target” subgroup (70% vs 64% vs 56% satisfied in no 
target, pragmatic, and aspirational subgroups, respectively; 
P=0.0040; Table 3). However, in the RA diagnosis $2 years 
subset, while physician-reported satisfaction with RA control 
differed significantly across T2T subgroups, it was highest 
in the aspirational subgroup (79% vs 63% vs 82% satisfied 
in the no target, pragmatic, and aspirational subgroups, 
respectively; P,0.0001; Table 3).
Discussion
These data from the Adelphi 2014 RA DSP study provide 
valuable insights into the factors affecting treatment adjust-
ments in RA management in current European practices. 
For instance, escalation of treatment from csDMARD to 
bDMARD seems to be triggered by worsening of the disease 
rather than high baseline RA activity. Current recommenda-
tions in RA management, however, advise that physicians 
should aim for remission or LDA in order to prevent further 
damage.2,3 This study suggests that the goals of early inter-
vention and optimal disease control are not satisfactorily 
achieved in these patients.
A large proportion of patients did not receive any 
bDMARDs even though they experienced pain and their 
condition was perceived as “moderate-to-severe” by phy-
sicians. The reason for this requires further investigation. 
When bDMARD therapy was prescribed, first and second 
bDMARDs were chosen according to the perceived effi-
cacy and safety of the bDMARD derived from clinical 
trial data and/or the individual physician’s professional 
experience, which is in agreement with the results from a 
previous study.17
In our analysis sample, 68% of those patients who had 
previously received a bDMARD had only ever received 
one bDMARD therapy (n=926), even if 1,438 patients had 
moderate-to-severe RA and were considered potentially 
eligible for bDMARD at the initiation of current treatment. 
Previous studies have shown that initial treatment with TNF 
inhibitors can fail due to intolerance, inefficacy, or loss of 
efficacy, and that prior exposure to TNF inhibitors results in 
a decline in the proportion of patients responding to subse-
quent biologic treatment, including a decline of about 10% 
in ACR categorical response criteria for the same class of 
bDMARDs.18,19 Such observations may delay a physician’s 
decision to switch to other bDMARDs. However, switch-
ing to another drug of this group may still be beneficial in 
some patients.18 Indeed, an immediate switch to a second 
bDMARD within the TNF inhibitor class after failure of 
the first bDMARD has previously proven to be effective in 
achieving better disease control in approximately 60% of the 
nonresponders to first bDMARD.20
In the T2T adoption analysis, a T2T approach was not 
adopted in almost half of the patients with RA even though 
Table 2 Clinical characteristics of patients according to DMARD therapy group
Characteristics Overall 
(N=2,410)
Currently on 
non-bDMARD (n=1,551)
Currently on 
bDMARD (n=859)
P-value
Time since diagnosis, years, mean (SD)
Missing
5.95 (6.68)
141
4.76 (6.39)
79
8.13 (6.67)
62
,0.0001a
Disease severity at initiation of current treatment, n (%)
Mild
Moderate
severe
324 (13)
1,358 (56)
728 (30)
292 (19)
942 (61)
317 (20)
32 (4)
416 (48)
411 (48)
,0.0001b
level of pain at initiation of current treatment 
(1= none; 10= worst), mean (SD)
6.17 (2.17) 5.72 (2.22) 7.00 (1.82) ,0.0001a
Characteristics of bDMARD-eligiblec patients Overall 
(n=1,438)
Currently on 
non-bDMARD (n=796)
Currently on 
bDMARD (n=642)
P-value
Time since diagnosis, years, mean (SD)
Missing
7.54 (7.21)
99
6.69 (7.40)
49
8.62 (6.82)
50
,0.0001a
Disease severity at initiation of current treatment, n (%)
Moderate
severe
895 (62)
543 (38)
585 (73)
211 (27)
310 (48)
332 (52)
,0.0001b
level of pain at initiation of current treatment
(1= none; 10= worst), mean (SD)
6.75 (1.77) 6.44 (1.80) 7.13 (1.65) ,0.0001a
Notes: aMann–Whitney U test. bchi-squared test. cPatients were considered to be eligible for bDMARD treatment if they had moderate-to-severe RA at the initiation of 
the current treatment, had previously received a csDMARD, and had been on the current treatment for $6 months. Additionally, the physician had to be authorized to 
initiate bDMARDs.
Abbreviations: bDMARD, biologic disease-modifying antirheumatic drug; csDMARD, conventional synthetic disease-modifying antirheumatic drug; RA, rheumatoid arthritis.
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Figure 1 Factors influencing bDMARD treatment start.
Notes: Physicians could respond with more than one reason. (A) Physician-reported reasons for the choice of first-line bDMARD. Overall N=629. (B) Physician-reported 
reasons for switching previous bDMARD for current/most recent bDMARD. Overall N=297; physicians could only provide a reason for switching in the 297 patients who 
received two or more bDMARDs. (C) Physician-reported reasons that would prompt initiation of bDMARD therapy in bDMARD-naïve patients. Overall N=495.
Abbreviations: bDMARD, biologic disease-modifying antirheumatic drug; DAS, disease activity score.
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previous studies showed that knowledge and implementa-
tion of T2T are both high among rheumatologists.21–23 Even 
when a T2T approach was implemented, it was mostly used 
in patients with $2 years since RA diagnosis rather than 
in those with early disease (ie, RA diagnosis ,2 years). 
However, a T2T approach is particularly recommended 
during the early phase of the disease when RA is not yet 
established and optimum disease control is more readily 
achieved, thereby preventing joint damage. The reasons 
for poor adoption of T2T recommendations in 201424 can 
only be speculative because this specific question was not 
investigated. However, potential reasons include physician 
Table 3 Baseline characteristics of patients across different T2T subgroups
Characteristics RA diagnosis ,2 years, n=579 RA diagnosis $2 years, n=1,802
T2T approach T2T approach
None
335 (58)
Pragmatic
45 (8)
Aspirational
199 (34)
P-value None
809 (45)
Pragmatic
350 (19)
Aspirational
643 (36)
P-value
Age, years, mean (SD)
Missing
51.23 (14.49)
3
42.58 (11.94)
0
43.96 (14.80)
0
,0.0001 56.89 (13.62)
5
51.91 (14.06)
0
51.18 (13.29)
0
,0.0001a
Sex, n (%)
Female
Missing
224 (67)
0
39 (87)
0
153 (77)
0
0.0032
553 (68)
0
258 (74)
0
475 (74)
0
0.0386b
Current severity, n (%) 0.1375 ,0.0001a
Mild
Moderate
severe
Missing
205 (61)
115 (34)
15 (4)
0
23 (51)
16 (36)
6 (13)
0
113 (57)
65 (33)
21 (11)
0
583 (72)
202 (25)
24 (3)
0
199 (57)
135 (39)
16 (5)
0
521 (81)
107 (17)
15 (2)
0
Disease severity at initiation of current treatment, n (%) ,0.0001 ,0.0001a
Mild
Moderate
severe
Missing
110 (33)
172 (51)
53 (16)
0
12 (27)
25 (56)
8 (18)
0
16 (8)
130 (65)
53 (27)
0
93 (11)
480 (59)
236 (29)
0
81 (23)
151 (43)
118 (34)
0
24 (4)
375 (58)
244 (38)
0
Disease severity at diagnosis, n (%) ,0.0001 ,0.0001a
Mild
Moderate
severe
Missing
115 (34)
169 (50)
51 (15)
0
12 (27)
27 (60)
6 (13)
0
19 (10)
127 (64)
53 (27)
0
97 (12)
476 (59)
236 (29)
0
84 (24)
167 (48)
99 (28)
0
37 (6)
404 (63)
202 (31)
0
Time since diagnosis, 
years, mean (SD)
0.42 (0.43) 0.65 (0.36) 0.53 (0.41) 0.0002 8.15 (7.42) 8.23 (7.64) 7.23 (5.74) 0.4496a
Missing 0 0 0 0 0 0
Current treatment, n (%) 0.9156 ,0.0001b
Non-bDMARDs
bDMARDs
Missing
297 (92)
27 (8)
11
40 (93)
3 (7)
2
174 (91)
17 (9)
8
481 (62)
298 (38)
30
185 (58)
135 (42)
30
295 (48)
317 (52)
31
Duration of current treatment, 
months, mean (SD)
4.63 (5.03) 8.53 (14.04) 6.88 (10.49) ,0.0001 29.28 (27.76) 24.43 (23.81) 25.07 (23.51) 0.0041a
Missing 11 2 8 30 30 31
Lines of bDMARD therapy, n (%) 0.9165 ,0.0001a
none
1
2
3+
Missing
307 (92)
28 (8)
0
0
0
42 (93)
3 (7)
0
0
0
182 (91)
17 (9)
0
0
0
496 (61)
212 (26)
78 (10)
23 (3)
0
194 (55)
85 (24)
57 (16)
14 (4)
0
305 (47)
239 (37)
67 (10)
32 (5)
0
Time to first bDMARD if ever 
received, months, mean (SD)
4.78 (4.02) 5.00 (2.65) 3.86 (3.58) 0.6786 67.35 (68.35) 80.72 (80.93) 59.46 (61.57) 0.0146a
Missing 307 42 187 502 195 312
Physician satisfaction with RA control, n (%) 0.0040 ,0.0001b
Not satisfied
Satisfied
Missing
99 (30)
236 (70)
0
16 (36)
29 (64)
0
87 (44)
112 (56)
0
172 (21)
637 (79)
0
130 (37)
220 (63)
0
113 (18)
530 (82)
0
Notes: aKruskal–Wallis test. bchi-squared test.
Abbreviations: bDMARD, biologic disease-modifying antirheumatic drug; RA, rheumatoid arthritis; T2T, treat-to-target.
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and/or patient dissatisfaction with therapeutic targets that 
concentrate solely on the attainment of disease activity states 
as recently published.25 Clinical time constraints precluding 
the ability to book frequent patient follow-ups that assess 
components of composite DASs can also contribute.
In terms of RA control, physicians’ satisfaction was 
highest in patients who had been diagnosed with RA $2 years 
compared with those with RA diagnosis ,2 years. In the RA 
diagnosis $2 years subset, the use of bDMARDs was also 
higher than in the RA diagnosis ,2 years subgroup. This 
suggests that the lower satisfaction with outcome in early 
disease may be associated with delayed use of bDMARDs, 
although other factors could play a role as well.
In terms of limitations, this study was conducted in 
selected European countries and the results may not be an 
accurate reflection of other international practices. Fur-
thermore, the sample may not be entirely representative of 
the practicing population of rheumatologists because the 
physicians participating in the DSP were those who met 
minimum workload criteria (regarding the number of RA 
patients they treat) for recruitment purposes. A certain degree 
of bias is expected because assessment of current disease 
activity relies on the physicians’ accuracy in interpreting and 
reporting information. Therefore, patients of physicians who 
took part in this study may have characteristics that differ 
from those of physicians who declined to participate, thereby 
reducing the generalizability of the findings.
Conclusion
This cross-sectional analysis shows that the use of bDMARDs 
is suboptimal in patients with RA and that a T2T approach 
is not universally adopted.
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